Sandra Fernandes Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandra Fernandes Dias has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Luca Regli
Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland
5 shared publicationsElisabeth Jehli
Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland
3 shared publications- Elisabeth Jehli
Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland
2 shared publications - Giuseppe Esposito
Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, 8091 Zurich, Switzerland
2 shared publications - Johannes Sarnthein
Zurich Neuroscience Center Eidgenössische Technische Hochschule Zürich and University of Zurich Zurich Switzerland
2 shared publications - Oliver Bozinov
Department of Neurosurgery, HOCH Health Ostschweiz, Kantonsspital St.Gallen, University Teaching and Research Hospital, St.Gallen, Switzerland
2 shared publications
Latest Publications
- Open Access
- 14 June 2026
- Published by Elsevier in World Neurosurgery
- Vol. 212, 125133
In Reply to the Letter to the Editor Regarding “Comparative Analysis of Repeat Cranial Imaging in Mild Traumatic Brain Injury: Evaluating Risk Factors, Costs, and Radiation Exposure Between 2017 and 2023”
- 14 June 2026
- Published by Elsevier in World Neurosurgery
- Vol. 212, 125133
Open AccessIn Reply to the Letter to the Editor Regarding “Comparative Analysis of Repeat Cranial Imaging in Mild Traumatic Brain Injury: Evaluating Risk Factors, Costs, and Radiation Exposure Between 2017 and 2023”
- Open Access
- 16 May 2026
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- p. 1-19
Ventricle width and cerebrospinal fluid diversion rate after open fetal spina bifida repair – a four year follow-up
Objective: To assess the postnatal cerebrospinal fluid diversion (CSFD) rates and associated prenatal risk factors (RF) in patients with open fetal spina bifida (fSB) repair over a 4-year follow-up. Methods: In 185 patients, CSFD rate was determined at one year, and incremental risk (IR) for CSFD at 2 and 4 years. Characteristics of children without CSFD were compared to those with CSFD, and multiple regression analysis evaluated RF. Results: Sixty-four children (35%) needed CSFD within the first year. These children had larger head circumference (HC) at screening (p=0.001) and before delivery (p<0.001), and larger ventricles at screening (Vp-screening), and before delivery (Vp-delivery) (each p<0.001). Multiple regression identified only Vp-screening, Vp-delivery and their delta as independent RF for CSFD. Vp values were higher in children needing CSFD within the first year compared with years 2-4 (p<0.001 and p=0.01), and larger Vp was associated with earlier CSFD in the first year (p = 0.02). IR for CSFD declined over follow-up. Conclusion: The 1-year CSFD rate after open fSB repair was 35%, with decreasing IR through year four. Larger Vp at screening and before delivery, and their delta, were independent RF for CSFD, while HC was not.
- 16 May 2026
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- p. 1-19
Open AccessVentricle width and cerebrospinal fluid diversion rate after open fetal spina bifida repair – a four year follow-up
Objective: To assess the postnatal cerebrospinal fluid diversion (CSFD) rates and associated prenatal risk factors (RF) in patients with open fetal spina bifida (fSB) repair over a 4-year follow-up. Methods: In 185 patients, CSFD rate was determined at one year, and incremental risk (IR) for CSFD at 2 and 4 years. Characteristics of children without CSFD were compared to those with CSFD, and multiple regression analysis evaluated RF. Results: Sixty-four children (35%) needed CSFD within the first year. These children had larger head circumference (HC) at screening (p=0.001) and before delivery (p<0.001), and larger ventricles at screening (Vp-screening), and before delivery (Vp-delivery) (each p<0.001). Multiple regression identified only Vp-screening, Vp-delivery and their delta as independent RF for CSFD. Vp values were higher in children needing CSFD within the first year compared with years 2-4 (p<0.001 and p=0.01), and larger Vp was associated with earlier CSFD in the first year (p = 0.02). IR for CSFD declined over follow-up. Conclusion: The 1-year CSFD rate after open fSB repair was 35%, with decreasing IR through year four. Larger Vp at screening and before delivery, and their delta, were independent RF for CSFD, while HC was not.
- Open Access
- 20 April 2026
- Published by Elsevier in World Neurosurgery
- Vol. 211, 124993
Comparative Analysis of Repeat Cranial Imaging in Mild Traumatic Brain Injury: Evaluating Risk Factors, Costs, and Radiation Exposure Between 2017 and 2023
- 20 April 2026
- Published by Elsevier in World Neurosurgery
- Vol. 211, 124993
Open AccessComparative Analysis of Repeat Cranial Imaging in Mild Traumatic Brain Injury: Evaluating Risk Factors, Costs, and Radiation Exposure Between 2017 and 2023
- Open Access
- 7 October 2025
- Published by Elsevier in World Neurosurgery
- Vol. 204, 124532
Long-Term Follow-up in Idiopathic Normal Pressure Hydrocephalus—Towards a more Comprehensive Disease Outcome
- 7 October 2025
- Published by Elsevier in World Neurosurgery
- Vol. 204, 124532
Open AccessLong-Term Follow-up in Idiopathic Normal Pressure Hydrocephalus—Towards a more Comprehensive Disease Outcome
- Open Access
- 15 June 2023
- Published by Wiley in United European Gastroenterology Journal
- Vol. 11 (6) , 531-541
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
Background: Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD.Objective: We aimed to evaluate the performance of readily available biomarkers and develop risk matrices to predict CD progression.Methods: Data from 289 CD patients receiving infliximab (IFX) maintenance therapy for 2 years was collected; those patients were included in DIRECT, a prospective multicenter observational study. Disease progression was evaluated using two composite outcomes incorporating clinical and drug‐related factors, the first including IFX dose and/or frequency adjustments. Univariate and multivariable logistic regressions were used to calculate the odds ratios (OR) and to develop risk matrices.Results: The isolated presence of anemia at least once during follow‐up was a significant predictor of disease progression (OR 2.436 and 3.396 [p ≤ 0.001] for composite outcomes 1 and 2, respectively) regardless of confounding factors. Isolated highly elevated C‐reactive protein (CRP; >10.0 mg/L) and fecal calprotectin (FC; >500.0 μg/g) in at least one visit were also significant predictors, while milder elevations (3.1–10.0 mg/L and 250.1–500.0 μg/g) were only relevant when detected in at least two visits (consecutive or not). The combination of biomarkers in risk matrices had good ability to predict progression; patients simultaneously presenting anemia, highly elevated CRP and FC at least once had 42%–63% probability of achieving the composite outcomes.Conclusion: The combined evaluation of hemoglobin, CRP, and FC in at least one time point and their incorporation into risk matrices seems to be the optimal strategy for CD management, as data from additional visits did not meaningfully influence the predictions and may delay decision‐making.
- 15 June 2023
- Published by Wiley in United European Gastroenterology Journal
- Vol. 11 (6) , 531-541
Open AccessHow many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
Background: Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD.Objective: We aimed to evaluate the performance of readily available biomarkers and develop risk matrices to predict CD progression.Methods: Data from 289 CD patients receiving infliximab (IFX) maintenance therapy for 2 years was collected; those patients were included in DIRECT, a prospective multicenter observational study. Disease progression was evaluated using two composite outcomes incorporating clinical and drug‐related factors, the first including IFX dose and/or frequency adjustments. Univariate and multivariable logistic regressions were used to calculate the odds ratios (OR) and to develop risk matrices.Results: The isolated presence of anemia at least once during follow‐up was a significant predictor of disease progression (OR 2.436 and 3.396 [p ≤ 0.001] for composite outcomes 1 and 2, respectively) regardless of confounding factors. Isolated highly elevated C‐reactive protein (CRP; >10.0 mg/L) and fecal calprotectin (FC; >500.0 μg/g) in at least one visit were also significant predictors, while milder elevations (3.1–10.0 mg/L and 250.1–500.0 μg/g) were only relevant when detected in at least two visits (consecutive or not). The combination of biomarkers in risk matrices had good ability to predict progression; patients simultaneously presenting anemia, highly elevated CRP and FC at least once had 42%–63% probability of achieving the composite outcomes.Conclusion: The combined evaluation of hemoglobin, CRP, and FC in at least one time point and their incorporation into risk matrices seems to be the optimal strategy for CD management, as data from additional visits did not meaningfully influence the predictions and may delay decision‐making.
- 22 April 2021
- Published by Springer Nature in Child's Nervous System
- Vol. 37 (6) , 1883-1893
Ventriculomegaly in children: nocturnal ICP dynamics identify pressure-compensated but active paediatric hydrocephalus
Introduction Paediatric ventriculomegaly without obvious signs or symptoms of raised intracranial pressure (ICP) is often interpreted as resulting from either relative brain atrophy, arrested “benign” hydrocephalus, or “successful” endoscopic third ventriculostomy (ETV). We hypothesise that the typical ICP “signature” found in symptomatic hydrocephalus can be present in asymptomatic or oligosymptomatic children, indicating pressure-compensated, but active hydrocephalus. Methods A total of 37 children fulfilling the mentioned criteria underwent computerised ICP overnight monitoring (ONM). Fifteen children had previous hydrocephalus treatment. ICP was analysed for nocturnal dynamics of ICP, ICP amplitudes (AMP), magnitude of slow waves (SLOW), and ICP/AMP correlation index RAP. Depending on the ONM results, children were either treated or observed. The ventricular width was determined at the time of ONM and at 1-year follow-up. Results The recordings of 14 children (group A) were considered normal. In the 23 children with pathologic recordings (group B), all ICP values and dependent variables (AMP, SLOW) were significantly higher, except for RAP. In group B, 12 of 15 children had received a pre-treatment and 11 of 22 without previous treatment. All group B children received treatment for hydrocephalus and showed a significant reduction of frontal-occipital horn ratio at 1 year. During follow-up, a positive neurological development was seen in 74% of children of group A and 100% of group B. Conclusion Ventriculomegaly in the absence of signs and symptoms of raised ICP was associated in 62% of cases to pathological ICP dynamics. In 80% of pre-treated cases, ETV or shunt failure was found. Treating children with abnormal ICP dynamics resulted in an outcome at least as favourable as in the group with normal ICP dynamics. Thus, asymptomatic ventriculomegaly in children deserves further investigation and, if associated with abnormal ICP dynamics, should be treated in order to provide a normalised intracranial physiology as basis for best possible long-term outcome.
- 22 April 2021
- Published by Springer Nature in Child's Nervous System
- Vol. 37 (6) , 1883-1893
Ventriculomegaly in children: nocturnal ICP dynamics identify pressure-compensated but active paediatric hydrocephalus
Introduction Paediatric ventriculomegaly without obvious signs or symptoms of raised intracranial pressure (ICP) is often interpreted as resulting from either relative brain atrophy, arrested “benign” hydrocephalus, or “successful” endoscopic third ventriculostomy (ETV). We hypothesise that the typical ICP “signature” found in symptomatic hydrocephalus can be present in asymptomatic or oligosymptomatic children, indicating pressure-compensated, but active hydrocephalus. Methods A total of 37 children fulfilling the mentioned criteria underwent computerised ICP overnight monitoring (ONM). Fifteen children had previous hydrocephalus treatment. ICP was analysed for nocturnal dynamics of ICP, ICP amplitudes (AMP), magnitude of slow waves (SLOW), and ICP/AMP correlation index RAP. Depending on the ONM results, children were either treated or observed. The ventricular width was determined at the time of ONM and at 1-year follow-up. Results The recordings of 14 children (group A) were considered normal. In the 23 children with pathologic recordings (group B), all ICP values and dependent variables (AMP, SLOW) were significantly higher, except for RAP. In group B, 12 of 15 children had received a pre-treatment and 11 of 22 without previous treatment. All group B children received treatment for hydrocephalus and showed a significant reduction of frontal-occipital horn ratio at 1 year. During follow-up, a positive neurological development was seen in 74% of children of group A and 100% of group B. Conclusion Ventriculomegaly in the absence of signs and symptoms of raised ICP was associated in 62% of cases to pathological ICP dynamics. In 80% of pre-treated cases, ETV or shunt failure was found. Treating children with abnormal ICP dynamics resulted in an outcome at least as favourable as in the group with normal ICP dynamics. Thus, asymptomatic ventriculomegaly in children deserves further investigation and, if associated with abnormal ICP dynamics, should be treated in order to provide a normalised intracranial physiology as basis for best possible long-term outcome.
- 1 February 2020
- Published by Elsevier in World Neurosurgery
- Vol. 134, 662-663
In Reply to the Letter to the Editor Regarding “Minipterional Craniotomy versus Supraorbital Technique for MCA Aneurysms”
- 1 February 2020
- Published by Elsevier in World Neurosurgery
- Vol. 134, 662-663
In Reply to the Letter to the Editor Regarding “Minipterional Craniotomy versus Supraorbital Technique for MCA Aneurysms”
- Open Access
- 1 February 2019
- Published by Elsevier in World Neurosurgery
- Vol. 122, 43-47
Multimodal Monitoring Strategy Is Decisive in Elective Middle Cerebral Artery Aneurysm Clipping: A Case Report
- 1 February 2019
- Published by Elsevier in World Neurosurgery
- Vol. 122, 43-47
Open AccessMultimodal Monitoring Strategy Is Decisive in Elective Middle Cerebral Artery Aneurysm Clipping: A Case Report
- 1 February 2019
- Published by Elsevier in World Neurosurgery
- Vol. 122, e349-e357
Selection Strategy for Optimal Keyhole Approaches for Middle Cerebral Artery Aneurysms: Lateral Supraorbital Versus Minipterional Craniotomy
- 1 February 2019
- Published by Elsevier in World Neurosurgery
- Vol. 122, e349-e357
Selection Strategy for Optimal Keyhole Approaches for Middle Cerebral Artery Aneurysms: Lateral Supraorbital Versus Minipterional Craniotomy
- Open Access
- 1 July 2018
- Published by Elsevier in World Neurosurgery
- Vol. 115, e637-e644
Safeness and Utility of Concomitant Intraoperative Monitoring with Intraoperative Magnetic Resonance Imaging in Children: A Pilot Study
- 1 July 2018
- Published by Elsevier in World Neurosurgery
- Vol. 115, e637-e644
Open AccessSafeness and Utility of Concomitant Intraoperative Monitoring with Intraoperative Magnetic Resonance Imaging in Children: A Pilot Study